AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05963048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion 1000 mg
Study NCT05963048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL6 inhibitor
Description: 6 mg/kg I V infusion monthly
Study NCT04079660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary blood glucose blood draw
Description: Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
Study NCT05556902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent Epidural Spinal Cord Stimulation
Description: Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
Study NCT05578014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
Study NCT04998786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
Study NCT04998786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
Study NCT04998786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
Study NCT06218303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Peptide Vaccine
Description: MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
Study NCT06218303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol®
Description: A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
Study NCT06218303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
Study NCT06218303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
Study NCT06309316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC)
Description: In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
Study NCT04785157 — intervention group
Intervention type: BIOLOGICAL
Intervention: serology testing profiles description
Description: SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
Study NCT04785157 — intervention group
Intervention type: BIOLOGICAL
Intervention: immune response characterization
Description: systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
Study NCT04785157 — intervention group
Intervention type: OTHER
Intervention: in vivo brain PET-TSPO acquisitions
Description: in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
Study NCT04785157 — intervention group
Intervention type: OTHER
Intervention: brain MRI assessment
Description: structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
Study NCT04785157 — intervention group
Intervention type: BEHAVIORAL
Intervention: neurocognitive assessment
Description: multi-domains neurocognitive assessment
Study NCT05503251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05503251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Assessment
Description: Undergo neuropsychological evaluation
Study NCT05503251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05503251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05503251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05503251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04784884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSI
Description: diagnostic hyperspectral imaging
Study NCT05510024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy
Description: The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
Study NCT05510024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCIT
Description: Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
Study NCT06407024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic transabdominal adrenalectomy
Description: Adrenalectomy performed by laparoscopic approach
Study NCT06407024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic transabdominal adrenalectomy
Description: Adrenalectomy performed by robotic approach
Study NCT04783012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter removal
Description: Catheter management strategy after surgery
Study NCT04783012 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter removal
Description: Catheter management strategy after surgery
Study NCT05173779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial isolation by catheter ablation
Description: Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
Study NCT06652295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive physiotherapy (CDP)
Description: CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.
Study NCT06652295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered Complex Decongestive Physiotherapy (CDP)
Description: The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
Study NCT05411497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MUC1-activated T-cells
Description: Given IV
Study NCT05411497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06650384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin
Description: Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
Study NCT04357951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
Study NCT05473000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Submaximal and maximal exercise
Study NCT05473000 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Submaximal and maximal exercise
Study NCT05473000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Delivery of ozone air pollution at 170ppb
Study NCT06650384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
Description: Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
Study NCT06662279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Rapid Palatal Expander
Description: Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander
Study NCT06662279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Banded Palatal Expander
Description: Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
Study NCT06586281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
Study NCT04357951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
Study NCT04357951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
Study NCT04357951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy
Description: All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
Study NCT06525545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early mobilizzation of the ankle
Description: perform flexion-extension exercises of the operated ankle
Study NCT04971577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin 40mg
Description: participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
Study NCT06525545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early mobilizzation of the ankle
Description: perform flexion-extension exercises of the operated ankle
Study NCT04971577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
Study NCT06663501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assisted Motion with Enhanced Sensation training
Description: During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
Study NCT06663501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Motion with Enhanced Sensation training
Description: During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
Study NCT06333496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLP-1 Booster (GB)
Description: GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
Study NCT03972527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
Study NCT06403956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with video
Description: The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the video group with the hand washing video developed by the researchers within the scope of the course. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
Study NCT06403956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with paint
Description: The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the paint group with the demonstration method using acrylic paint instead of soap. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
Study NCT05500807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emicizumab
Description: Subcutaneous injection of emicizumab for prophylaxis
Study NCT04985136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab；Rivoceranib
Description: Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
Study NCT04985136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivoceranib
Description: Rivoceranib mesylate (750 mg, QD, po)
Study NCT04985136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib tosylate (400 mg, twice a day (BID), po)
Study NCT04985136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
Study NCT05080959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL-01
Description: Subjects will receive a single dose
Study NCT05080959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naropin 150 MG Per 20 ML Injection
Description: Subjects will receive a single dose
Study NCT05080959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a single dose
Study NCT03972527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Oral Care and Analgesia
Description: Standard oral care, oral hygiene and oral pain protocols
Study NCT04197544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoFAVI
Description: EndoFAVI creation to patients that require vascular access for hemodialysis.
Study NCT05181540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-205
Description: Allogeneic genetically engineered human umbilical vein endothelial cells
Study NCT05181540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03972527 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine Oral Care and Analgesia
Description: Standard oral care, oral hygiene and oral pain protocols
Study NCT04840706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC Airvo
Description: HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
Study NCT04840706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: No HFNC treatment
Study NCT06677892 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study NCT06666231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL (quadratus lumborum) block administration
Description: After endotracheal intubation, patients in the supine position will be given a lateral tilt and the areas to be treated will be cleaned with surgical antiseptic solution. The convex USG probe will be covered in a sterile manner. Then, the sterile probe will be placed transversely on the crista iliaca. The probe will be directed cranially until the external oblique muscle, internal oblique muscle and transverse abdominis muscle are clearly visualized. The psoas major muscle and the transverse process of the vertebra will be visualized. The QL muscle will be visualized between the aponeuros of the transverse abdominis muscle and the psoas major muscle. A 20 G 100 mm block needle will be advanced from posterolateral to anteromedial using the in-plane technique. The needle will be directed between the QL muscle and the psoas major muscles. 20 ml of 0.25% bupivacaine (Buvasin®, Vem İlaç, Turkey) will be injected on each side between the fasciae of these two muscles and the LA distribution
Study NCT06666231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Oblique Intercostal Plane Block
Description: After endotracheal intubation, a 20-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
Study NCT05622942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBPV
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
Study NCT05622942 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
Study NCT05473000 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: Delivery of room air
Study NCT05368129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon dilation
Description: Balloon dilation was performed after DES implantation.